The Center for Cellular and Molecular Diagnostics focuses on developing and validating integrated nanotechnique-based strategies to identify novel biomarkers in non-invasive or minimally invasive clinical samples and to translate these findings into clinical assays that provide information suitable for personalized medicine approaches. The center’s goal is to fill critical gaps that persist in early disease detection, prognostic evaluation, and the real-time monitoring of treatment responses for several important infectious and chronic diseases, including tuberculosis and many cancers, in order to improve patient outcomes.

Our research targets the:

  1. Identification and validation of new biomarkers for early disease diagnosis and/or rapid evaluation of disease responses;
  2. Development of novel nanotech-based approaches to improve mass spectrometry analyses;
  3. Refinement and translation of cutting-edge technologies to new clinical applications, including point-of-care and operating room diagnostics;
  4. The development and validation of novel nanosensor platforms suitable for early detection and prevention approaches. In order to accomplish these goals, we have assembled a diverse team of scientists with expertise in biochemistry, biomedical engineering, nanofabrication, and mass spectrometry, as well as several other fields of research relevant to the goals of the center.